Skip to main content
20 minutes minimum delay
toggle main navigation
Our Approach
Our Approach
NDMA Receptors
Therapeutic Area Focus
Pipeline
Clinical Studies
Investors
About Us
About Aptinyx
Leadership Team
Board of Directors
Working at Aptinyx
Contact Us
Site Search
Press Releases
Investor Relations
Press Releases
Events & Presentations
Stock Information
Stock Quote
Stock Chart
Historical Stock Quote
Analyst Coverage
Financials & Filings
Quarterly Results
Annual Reports & Proxy
SEC Filings
Governance
Governance Documents & Charters
Executive Management
Board of Directors
Committee Composition
FAQ & Contacts
Investor Contacts
Investor FAQs
Investor Email Alerts
RSS Feeds
Normal
Press release year list
2021
2020
2019
2018
2017
2016
2015
January 19, 2021
Aptinyx Announces Publication of Review Article Highlighting Preclinical Data in Medicine in Drug Discovery Demonstrating the Potential of NYX-2925 to Treat Chronic, Centralized Pain Conditions
Download
PDF format download (opens in new window)
January 05, 2021
Aptinyx to Participate in H.C. Wainwright BioConnect 2021 Conference
Download
PDF format download (opens in new window)
January 04, 2021
Aptinyx Announces Recommencement of Phase 2 Study of NYX-2925 in Patients With Painful Diabetic Peripheral Neuropathy
Download
PDF format download (opens in new window)